Diabetic foot ulcers arise from neuropathy and/or ischaemia. The diabetic foot is associated with cardiovascular
disease (CVD) and excess mortality. Lipid-lowering therapy reduces CVD morbidity and mortality in diabetic patients
with foot ulcers. In particular, statins decrease CVD mortality and improve survival in diabetic foot patients, while fibrates
benefit patients with a specific lipid profile. Statins reduce progression of the local disease, improving symptoms and
reducing amputations, mainly due to their impact on peripheral arterial disease. Fibrates appear to reduce amputations by
improving neuropathy. They also improve ulcer healing and reduce recurrence. This review assesses the role of hypolipidaemic
treatment in diabetic foot patients.
Keywords: Diabetes mellitus, diabetic foot, dyslipidaemia, fibrates, hypolipidaemic treatment, statins.
Rights & PermissionsPrintExport